NIAID Clinical Trial Implementation (U01) Cooperative Agreement | Apply Online

Opportunity Summary:

The NIAID Clinical Trial Implementation (U01) Cooperative Agreement (Funding Opportunity Number PAR 05 113) is a National Institutes of Health funding opportunity focused specifically on supporting the actual conduct and execution of investigator-initiated clinical trials in areas aligned with NIAID priorities, including allergy, immunology, transplantation, microbiology, and infectious diseases. It sits downstream of NIAID's Clinical Trial Planning Grant mechanism (R34). In practical terms, this opportunity is designed to move a study from the planning and final-preparation phase into the real-world implementation phase, where participants are enrolled, interventions are delivered, outcomes are collected, and the full clinical trial is managed and monitored.

A defining feature of this opportunity is that applications are only accepted from investigators who already hold an NIAID Clinical Trial Planning (R34) award. Starting with the May 1, 2006 receipt date for AIDS-related applications and the June 1, 2006 receipt date for non-AIDS applications, NIAID limited eligibility for U01 clinical trial implementation submissions to R34 awardees. That restriction signals NIAID's intention to fund implementation only when the trial has already gone through a structured planning process with NIAID support, presumably to reduce avoidable delays, strengthen protocol quality, and increase the likelihood that a trial is ready to launch quickly and compliantly.

The required submission package emphasizes readiness to begin the trial. Applicants must use the PHS 398 grant application format along with special instructions, and they must include several key trial documents: an Institutional Review Board (IRB)-approved study protocol, an investigator's brochure (or an equivalent document describing the investigational product and its safety information), and a manual of operations (or equivalent) that lays out how the trial will be run day to day across sites and staff. These materials are not treated as optional add-ons; they are central to demonstrating that the trial is fully specified, operationally executable, and ethically cleared. The announcement also makes clear that all documents must satisfy the requirements and expectations of NIH as well as federal human subjects and clinical research regulators, specifically the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP). That reflects the reality that many NIAID-supported trials may involve regulated products, complex consent and safety oversight, and strict compliance obligations.

The funding mechanism is a cooperative agreement (U01), not a standard research project grant. This matters because a cooperative agreement typically involves substantial scientific or programmatic involvement by the funding institute during the performance of the project. While the specific roles are laid out in the full announcement, the general implication is that NIAID staff will collaborate with awardees more actively than under an investigator-driven R01 model, particularly around milestones, trial oversight, recruitment progress, data and safety monitoring, and regulatory or operational issues that can affect a trial's integrity and timelines. The overarching goal is to support high-quality execution while reducing the risk of implementation failures that can occur when large trials launch without tight coordination and oversight.

Another notable commitment in the announcement is speed. NIAID states that, to avoid delaying trial initiation, peer review and award decisions for the clinical trial implementation grant will be completed within four months of application receipt. That is an unusually explicit timeline compared with many grant programs, and it reflects the time-sensitive nature of clinical trials where site readiness, staffing, contracting, and participant recruitment windows can be affected by long review cycles. This shorter turnaround is meant to help investigators preserve momentum from the R34 planning phase and transition quickly into recruitment and trial operations.

Administratively, the opportunity is categorized as discretionary funding and falls under the health activity category. It lists CFDA numbers 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). It also specifies that there is no cost sharing or matching requirement, which means applicants are not required to contribute non-federal funds as a condition of the award. The announcement as provided includes key dates for posting and archiving, indicating it was posted December 2, 2008, with an original closing date of May 7, 2009, a current closing date of January 7, 2010, and an archive date of February 7, 2010. Those dates indicate the opportunity is historical/archived rather than currently open, but they are important for understanding the program structure and how NIAID organized the R34-to-U01 pipeline during that period.

Eligibility is broad in terms of organizational type, though still bounded by the requirement that applicants must be NIAID R34 planning grant awardees for the specific clinical trial being proposed for implementation. Eligible applicant organizations include nonprofit organizations (both 501(c)(3) and non-501(c)(3)), state and county governments, for-profit organizations other than small businesses, and additional categories such as eligible federal agencies, faith-based or community-based organizations, and non-U.S. entities (foreign organizations). This range suggests NIAID intended the mechanism to be usable across academic, governmental, community, and international research environments, which aligns with the global nature of infectious disease and immunology research and the frequent need to conduct trials in diverse settings.

Overall, PAR 05 113 is best understood as an implementation-stage clinical trial award that is deliberately gated by an earlier NIAID planning award, requires IRB-approved and operations-ready documentation at the time of submission, uses a cooperative agreement structure to enable closer NIAID involvement, and is designed to move quickly from application receipt to award so that trials can start without unnecessary administrative lag.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Morris K. Udall Parkinsons Disease Centers of Excellence (P50)

Previous opportunity: Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellows (F31) in Nursing Research

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 05 113

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 05 113) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 05 113", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.